CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced its intention to offer, subject to market and other conditions, $175 million aggregate principal amount of convertible senior notes due 2019 (the “Notes”) in a private placement. The Notes will be offered by the initial purchasers only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933 (the “Act”). ARIAD also intends to grant the initial purchasers of the Notes an option, exercisable for 30 days, to purchase up to an additional $50 million aggregate principal amount of the Notes on the same terms and conditions.
Help employers find you! Check out all the jobs and post your resume.
